ALSPW Spineway SAS

Spineway a Gold Sponsor at the SILACO Congress in Mexico - Organization of a special event with Latin American distributors

Spineway a Gold Sponsor at the SILACO Congress in Mexico - Organization of a special event with Latin American distributors

Press release        

Ecully, July 24, 2024 – 6 p.m.



Spineway a Gold Sponsor at the SILACO Congress in Mexico

Organization of a special event with Latin American distributors

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, is taking part in the (SILACO) Congress in Mexico from July 24 to 27, 2024 with two local partners, Spinemed and Mava. As a Gold Sponsor of this major event in Latin America, Spineway will increase its visibility among spine surgeons and professionals in this strategic region.

The day before the opening of the congress, the Group organized a distributors’ meeting with its Latin American partners, during which the Spineway teams presented their premium ranges: VEOS and KAPHORN posterior fixation systems and ESP prostheses (cervical and lumbar). Spineway product managers organized training sessions for distributors from Brazil, Mexico, Peru, Panama and Chile, giving them an opportunity to handle the instruments in the product ranges presented. This distributors’ meeting, initially organized during EUROSPINE, allowed the Group to mobilize its Latin American distributors and strengthen ties with the teams.     

A symposium on cervical disc arthroplasty will also be held on July 26 by one of Spineway's local partners (Mava), in the presence of Dr. Carlos Zamorano Borquez, one of the first surgeons to implant the ESP cervical prosthesis. It will focus on four themes: biomechanics with Dr. Zamorano Borquez, contraindications and experience with Dr. Morelos Rangel, hybrid cervical construction (fusion and arthroplasty) with Dr. Estrada Estrada, and long-term results of cervical arthroplasty with Dr. Alpizar Aguirre.

Spineway has chosen the SILACO Congress, which attracts a large number of participants from all over Latin America every year, to showcase its VEOS platform, its KAPHORN range for posterior arthrodesis, its ACIFBOX cages for anterior cervical arthrodesis and its ESP prostheses (cervical and lumbar) for total disc replacements. Spineway will also present its latest innovations designed to meet the specific needs of Latin American patients.

Through these events, Spineway aims to strengthen its presence and the positioning of its products in Latin America, a historic region for the Group. These actions position Spineway as a key player in the sector and reinforce its aim of becoming a major player in less invasive spine treatments.

Next event:

September 24, 2024 – H1 2024 results

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.

ISIN: FR001400BVK2 – ALSPW        

Contacts:





SPINEWAY



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060
 



AELIUM



Investor relations



Solène Kennis



Attachment



EN
24/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch